Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
- Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer entity characterized by a heterogeneous genetic landscape and an immunosuppressive tumor microenvironment. Recent advances in high-resolution single-cell sequencing and spatial transcriptomics technologies have enabled an in-depth characterization of both malignant and host cell types and increased our understanding of the heterogeneity and plasticity of PDAC in the steady state and under therapeutic perturbation. In this Review we outline single-cell analyses in PDAC, discuss their implications on our understanding of the disease and present future perspectives of multimodal approaches to elucidate its biology and response to therapy at the single-cell level.
Results
Figure1
Figure1 shows the pipeline to uncover pancreatic cancer heterogeneity and complexity.
Figure2
CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by sequencing) is a method to detect the cell surface antibodies with single-cell level.
INs-seq is a new technology to record scRNA and intracellular protein activity.
Figure3
Figure3 is very interesting which shows various seq method to explore genomics, transcriptomics, proteomics and epigenetics.
Figure4
Figure3 is very interesting which shows various seq method to explore genomics, transcriptomics, proteomics and epigenetics.